Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 57 minutes ago
0mins
Should l Buy PSTV?
Source: Newsfilter
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.000
Low
2.00
Averages
8.00
High
19.00
Current: 6.000
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
See More
Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostics
- Successful Medicare Enrollment: Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in Medicare and received a Provider Transaction Access Number (PTAN), marking a critical step in its commercialization strategy for the CNSide® Cerebrospinal Fluid assay platform, which is expected to significantly enhance the company's revenue potential in the U.S. market.
- Expanded Coverage: The Medicare enrollment allows CNSide Diagnostics to serve approximately half of the U.S. Medicare population, which not only improves patient access to testing but also paves the way for future entry into Medicare Advantage plans, thereby strengthening the company's competitive position in the market.
- Accelerated Pricing and Coverage Efforts: With enrollment secured, CNSide Diagnostics will actively engage with local Medicare Administrative Contractors (MACs) to pursue local coverage determinations (LCDs) and support pricing decisions under the Clinical Laboratory Fee Schedule (CLFS), optimizing revenue capture.
- Commercial Expansion Plans: The company aims to further broaden its coverage through national and regional payer contracts, targeting over 150 million covered lives by 2026, which will lay a solid foundation for future growth.
See More
CNSide Diagnostics Secures Coverage Agreement with Blue Shield of California
- Expanded Coverage: CNSide Diagnostics' new payer coverage agreement with Blue Shield of California increases the total covered lives for its CNSide® CSF Tumor Cell Enumeration assay from 75 million to 81 million, making significant progress towards the company's goal of 150 million covered lives by 2026, thereby enhancing patient access across the U.S.
- Accelerated Adoption: The agreement is expected to further accelerate the adoption of CNSide across oncology centers by reducing reimbursement barriers, enabling physicians to better diagnose and treat difficult-to-diagnose CNS cancers, which will ultimately improve patient outcomes.
- Enhanced Clinical Utility: The CNSide® assay platform has demonstrated superior clinical utility over conventional CSF cytology in nine peer-reviewed publications and the FORESEE clinical trial, enabling earlier and more accurate detection and monitoring of leptomeningeal metastases, which has been shown to reduce related healthcare costs by approximately 40%.
- Market Impact: Since its commercial launch in 2020, over 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, achieving a sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases, thereby solidifying its market position.
See More
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx
- Manufacturing Collaboration: Plus Therapeutics has initiated a partnership with SpectronRx at a GMP manufacturing facility in Indiana to support late-stage clinical manufacturing of Rhenium-186 and REYOBIQ, thereby enhancing the reliability of its supply chain.
- Technology Transfer Agreement: Under a previously executed Master Services Agreement (MSA), this collaboration includes the transfer of REYOBIQ manufacturing processes, Rhenium-186 isotope processing, and analytical methods, ensuring technical and regulatory support for future commercial-scale production.
- Production Capacity Enhancement: SpectronRx's facility will provide on-demand manufacturing capabilities, simplifying logistics across the radiopharmaceutical production process and improving coordination, which is crucial for Plus's development of REYOBIQ.
- Strategic Development Goals: Plus Therapeutics' CEO stated that this partnership will bolster manufacturing readiness for REYOBIQ, supporting the company's target to complete manufacturing scale-up by 2026, thus driving long-term growth in its radiotherapeutic business.
See More
Plus Therapeutics Appoints New Chief Development Officer
- Executive Appointment: Plus Therapeutics appointed Eric J Daniels, M.D. as Chief Development Officer on April 20, 2026, aiming to enhance the company's R&D capabilities in CNS cancers and drive business growth.
- Inducement Award Plan: Under the 2015 New Employee Incentive Plan, Daniels received 20,000 stock options and 20,000 restricted stock units (RSUs), incentivizing his long-term service and promoting team stability.
- Option Details: The stock options have an exercise price of $7.30 per share and vest over four years, with 25% vesting in the first year and the remainder vesting monthly, ensuring Daniels' ongoing contributions during his tenure.
- RSU Vesting Schedule: The RSUs vest over three years, with one-third vesting in the quarter following the first anniversary and the remaining units vesting ratably over the next eight quarters, further solidifying his commitment to the company's growth.
See More
Plus Therapeutics Stock Meets Nasdaq Minimum Bid Requirement
- Stock Price Compliance: Plus Therapeutics (PSTV) announced that its common stock has once again met Nasdaq's minimum bid requirement, with the closing price remaining above $1.00 per share for 10 consecutive trading days, indicating stability and market acceptance of the company's stock.
- Price Movement: PSTV's stock price rose approximately 2.9% in pre-market trading on Tuesday, reflecting a positive investor response to the latest announcement, which may enhance market confidence and attract more investor interest.
- Financial Performance Beat: Plus Therapeutics reported a GAAP EPS of -$0.29, beating expectations by $0.01, while revenue reached $5.21 million, exceeding forecasts by $0.14 million, demonstrating improvements in financial management and operational efficiency.
- Clinical Program Progress: The company's advancements in the REYOBIQ clinical program have also garnered market attention, indicating ongoing efforts in drug development that could lay the groundwork for future revenue growth.
See More
Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
See More
Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostics
- Successful Medicare Enrollment: Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in Medicare and received a Provider Transaction Access Number (PTAN), marking a critical step in its commercialization strategy for the CNSide® Cerebrospinal Fluid assay platform, which is expected to significantly enhance the company's revenue potential in the U.S. market.
- Expanded Coverage: The Medicare enrollment allows CNSide Diagnostics to serve approximately half of the U.S. Medicare population, which not only improves patient access to testing but also paves the way for future entry into Medicare Advantage plans, thereby strengthening the company's competitive position in the market.
- Accelerated Pricing and Coverage Efforts: With enrollment secured, CNSide Diagnostics will actively engage with local Medicare Administrative Contractors (MACs) to pursue local coverage determinations (LCDs) and support pricing decisions under the Clinical Laboratory Fee Schedule (CLFS), optimizing revenue capture.
- Commercial Expansion Plans: The company aims to further broaden its coverage through national and regional payer contracts, targeting over 150 million covered lives by 2026, which will lay a solid foundation for future growth.
See More
CNSide Diagnostics Secures Coverage Agreement with Blue Shield of California
- Expanded Coverage: CNSide Diagnostics' new payer coverage agreement with Blue Shield of California increases the total covered lives for its CNSide® CSF Tumor Cell Enumeration assay from 75 million to 81 million, making significant progress towards the company's goal of 150 million covered lives by 2026, thereby enhancing patient access across the U.S.
- Accelerated Adoption: The agreement is expected to further accelerate the adoption of CNSide across oncology centers by reducing reimbursement barriers, enabling physicians to better diagnose and treat difficult-to-diagnose CNS cancers, which will ultimately improve patient outcomes.
- Enhanced Clinical Utility: The CNSide® assay platform has demonstrated superior clinical utility over conventional CSF cytology in nine peer-reviewed publications and the FORESEE clinical trial, enabling earlier and more accurate detection and monitoring of leptomeningeal metastases, which has been shown to reduce related healthcare costs by approximately 40%.
- Market Impact: Since its commercial launch in 2020, over 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, achieving a sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases, thereby solidifying its market position.
See More
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx
- Manufacturing Collaboration: Plus Therapeutics has initiated a partnership with SpectronRx at a GMP manufacturing facility in Indiana to support late-stage clinical manufacturing of Rhenium-186 and REYOBIQ, thereby enhancing the reliability of its supply chain.
- Technology Transfer Agreement: Under a previously executed Master Services Agreement (MSA), this collaboration includes the transfer of REYOBIQ manufacturing processes, Rhenium-186 isotope processing, and analytical methods, ensuring technical and regulatory support for future commercial-scale production.
- Production Capacity Enhancement: SpectronRx's facility will provide on-demand manufacturing capabilities, simplifying logistics across the radiopharmaceutical production process and improving coordination, which is crucial for Plus's development of REYOBIQ.
- Strategic Development Goals: Plus Therapeutics' CEO stated that this partnership will bolster manufacturing readiness for REYOBIQ, supporting the company's target to complete manufacturing scale-up by 2026, thus driving long-term growth in its radiotherapeutic business.
See More
Plus Therapeutics Appoints New Chief Development Officer
- Executive Appointment: Plus Therapeutics appointed Eric J Daniels, M.D. as Chief Development Officer on April 20, 2026, aiming to enhance the company's R&D capabilities in CNS cancers and drive business growth.
- Inducement Award Plan: Under the 2015 New Employee Incentive Plan, Daniels received 20,000 stock options and 20,000 restricted stock units (RSUs), incentivizing his long-term service and promoting team stability.
- Option Details: The stock options have an exercise price of $7.30 per share and vest over four years, with 25% vesting in the first year and the remainder vesting monthly, ensuring Daniels' ongoing contributions during his tenure.
- RSU Vesting Schedule: The RSUs vest over three years, with one-third vesting in the quarter following the first anniversary and the remaining units vesting ratably over the next eight quarters, further solidifying his commitment to the company's growth.
See More
Plus Therapeutics Stock Meets Nasdaq Minimum Bid Requirement
- Stock Price Compliance: Plus Therapeutics (PSTV) announced that its common stock has once again met Nasdaq's minimum bid requirement, with the closing price remaining above $1.00 per share for 10 consecutive trading days, indicating stability and market acceptance of the company's stock.
- Price Movement: PSTV's stock price rose approximately 2.9% in pre-market trading on Tuesday, reflecting a positive investor response to the latest announcement, which may enhance market confidence and attract more investor interest.
- Financial Performance Beat: Plus Therapeutics reported a GAAP EPS of -$0.29, beating expectations by $0.01, while revenue reached $5.21 million, exceeding forecasts by $0.14 million, demonstrating improvements in financial management and operational efficiency.
- Clinical Program Progress: The company's advancements in the REYOBIQ clinical program have also garnered market attention, indicating ongoing efforts in drug development that could lay the groundwork for future revenue growth.
See More
